Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; and Belixos PROTECT for the needs of sun-damaged skin. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Leverkusen, DE
Size (employees)
81 (est)+38%
Biofrontera was founded in 2012 and is headquartered in Leverkusen, DE

Biofrontera Office Locations

Biofrontera has office in Leverkusen
Leverkusen, DE

Biofrontera Metrics

Biofrontera Summary

Market capitalization

€122.9 m

Closing share price

Biofrontera's current market capitalization is €122.9 m.

Biofrontera Market Value History

Biofrontera Company Life

You may also be interested in